PMID- 35625254
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2079-6382 (Print)
IS  - 2079-6382 (Electronic)
IS  - 2079-6382 (Linking)
VI  - 11
IP  - 5
DP  - 2022 Apr 30
TI  - Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients 
      with Chronic Kidney Disease.
LID - 10.3390/antibiotics11050610 [doi]
LID - 610
AB  - The optimal dosage of cefoperazone-sulbactam for patients with chronic kidney 
      disease (CKD) remains unclear. This study aimed to investigate two treatment 
      strategies of cefoperazone-sulbactam-2 g/2 g twice daily and adjusted dose 
      according to renal function for patients with CKD. A total of 155 patients with 
      CKD received cefoperazone-sulbactam either at a dose of 2 g/2 g twice daily 
      (study group) or adjusted according to renal function (control group) for the 
      treatment of acute bacterial infection. The primary outcome was the clinical 
      response rate at day 14 and the secondary outcomes included treatment failure and 
      all-cause death. The study group had a higher clinical response rate (80.0% vs. 
      65.0%) and a lower treatment failure rate (4.0% vs. 23.8%) as compared with the 
      control group. Further multivariable analysis showed that compared with the 
      control group, the study group had a higher clinical response rate (adjusted OR = 
      4.02; 95% CI, 1.49-10.81) and lower treatment failure rate (adjusted OR = 0.06; 
      95% CI, 0.01-0.28). In addition, no significant difference in all-cause mortality 
      was observed between the study and the control group (adjusted OR = 1.95; 95% CI, 
      0.57-6.66). Finally, no significant difference was observed between the study and 
      the control group in the risk of the adverse events (AEs)-diarrhea (p = 0.326), 
      eosinophilia (p = 1.000), prolonged PT (p = 0.674), alteration in renal function 
      (p = 0.938) and leukopenia (n = 0.938). In conclusion, cefoperazone-sulbactam at 
      a dose of 2 g/2 g twice daily could achieve better clinical efficacy than the 
      reduced dosage regimen. Additionally, this dosage did not increase the risk of AE 
      compared to the reduced dose. Therefore, cefoperazone-sulbactam at a dose of 2 
      g/2 g twice daily is an effective and safe regimen for acute bacterial infection 
      in patients with CKD.
FAU - Chao, Chien-Ming
AU  - Chao CM
AD  - Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan 
      73657, Taiwan.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AUID- ORCID: 0000-0002-6334-2388
AD  - Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan 
      Branch, Tainan 710, Taiwan.
FAU - Lee, Chen-Hsiang
AU  - Lee CH
AD  - Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang 
      Gung Memorial Hospital, Kaohsiung 833, Taiwan.
AD  - College of Medicine, Chang Gung University, Kaohsiung 833, Taiwan.
FAU - Tang, Hung-Jen
AU  - Tang HJ
AD  - Department of Medicine, Chi Mei Medical Center, Tainan 71004, Taiwan.
AD  - Department of Medical Research, Chi Mei Medical Center, Tainan 71004, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20220430
PL  - Switzerland
TA  - Antibiotics (Basel)
JT  - Antibiotics (Basel, Switzerland)
JID - 101637404
PMC - PMC9137919
OTO - NOTNLM
OT  - cefoperazone-sulbactam
OT  - chronic kidney disease
OT  - dose
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/29 06:00
MHDA- 2022/05/29 06:01
PMCR- 2022/04/30
CRDT- 2022/05/28 01:05
PHST- 2022/04/03 00:00 [received]
PHST- 2022/04/26 00:00 [revised]
PHST- 2022/04/29 00:00 [accepted]
PHST- 2022/05/28 01:05 [entrez]
PHST- 2022/05/29 06:00 [pubmed]
PHST- 2022/05/29 06:01 [medline]
PHST- 2022/04/30 00:00 [pmc-release]
AID - antibiotics11050610 [pii]
AID - antibiotics-11-00610 [pii]
AID - 10.3390/antibiotics11050610 [doi]
PST - epublish
SO  - Antibiotics (Basel). 2022 Apr 30;11(5):610. doi: 10.3390/antibiotics11050610.